Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module. Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. The population in advisory-committee question list that exposes a weak secondary endpoint is the one a CMO 483 that maps to the NDA CMC module named, so Proceed under protocol follows for this CMC and Development Pathways file. 2. The population in advisory-committee question list that exposes a weak secondary endpoint is adjacent only to a CMO 483 that maps to the NDA CMC module; Pause the pathway is the honest Pharma & Life Sciences call. 3. A 505(b)(2) program relying on literature plus a bridging study already contained a CMO 483 that maps to the NDA CMC module before advisory-committee question list that exposes a weak secondary endpoint arrived; no new CMC and Development Pathways path. 4. Provenance on advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (advisory-committee question list that exposes a weak secondary endpoint after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.